VEGFA and ovarian carcinoma: Anti-angiogenesis is also considered as promising target for the treatment of platinum-resistant ovarian cancer.[5] Bevacizumab, a FDA-approved monoclonal antibody targeting vascular endothelial growth factor (VEGF), and other compounds targeting tyrosine kinases are two major types of anti-angiogenesis agents.